Stockscreener 앱 받기
6.195
3.42%
0.205
전일 마감가:
$5.99
열려 있는:
$6.09
하루 거래량:
142.82K
Relative Volume:
0.06
시가총액:
$368.01M
수익:
-
순이익/손실:
$-130.41M
주가수익비율:
-2.7656
EPS:
-2.24
순현금흐름:
$-67.76M
1주 성능:
+12.64%
1개월 성능:
-11.75%
6개월 성능:
+38.28%
1년 성능:
+16.45%
1일 변동 폭
$5.995
$6.26
1주일 범위
$5.15
$6.26
52주 변동 폭
$3.21
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
명칭
Monte Rosa Therapeutics Inc
전화
617-949-2643
주소
321 HARRISON AVENUE, BOSTON
GLUE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
6.20 | 368.01M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.83 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.50 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
663.38 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.34 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.02 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 개시 | UBS | Buy |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
모두보기
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
Barclays PLC Acquires 43,499 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Growth in Short Interest - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Update - MarketBeat
Jane Street Group LLC Sells 51,005 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics provide corporate update, key milestones 2025 - Yahoo Finance
(GLUE) Technical Data - Stock Traders Daily
Monte Rosa outlines 2025 clinical milestones - Investing.com India
Monte Rosa outlines 2025 clinical milestones By Investing.com - Investing.com Australia
Monte Rosa Therapeutics Outlines 2025 Milestones and Financial Strength - TipRanks
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 - The Manila Times
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Acquired by Barclays PLC - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Acquired by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Purchases 197,247 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - MarketBeat
State Street Corp Raises Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term - Yahoo Finance
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Wells Fargo Downgrades Monte Rosa Therapeutics (GLUE) - MSN
Monte Rosa Therapeutics (NASDAQ:GLUE) Cut to Equal Weight at Wells Fargo & Company - MarketBeat
Charles Schwab Investment Management Inc. Boosts Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
The Manufacturers Life Insurance Company Buys 15,168 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Marketscreener.com
Monte Rosa Therapeutics appoints new board member - Investing.com
Monte Rosa Therapeutics appoints new board member By Investing.com - Investing.com UK
Monte Rosa Therapeutics Strengthens Board with Teva's R&D Chief, Advancing Molecular Glue Platform - StockTitan
Monte Rosa reports promising cancer therapy results By Investing.com - Investing.com Nigeria
Monte Rosa reports promising cancer therapy results - Investing.com
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - The Manila Times
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer - The Manila Times
Monte Rosa Therapeutics Announces Closing of Global License - GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at the - GlobeNewswire
Monte Rosa's Breakthrough Cancer Drug Shows Promise in Preclinical Data, Superior to Current Inhibitors - StockTitan
Intech Investment Management LLC Makes New $77,000 Investment in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
The 2nd Dimension: VC raises $500M fund for entrepreneurs pioneering life sci, tech - Fierce Biotech
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 8.7%Here's What Happened - MarketBeat
Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study - Yahoo Finance
Monte Rosa Therapeutics (GLUE) Price Target Increased by 5.66% to 16.32 - MSN
Monte Rosa reports favorable MRT-2359 trial results By Investing.com - Investing.com Nigeria
Monte Rosa reports favorable MRT-2359 trial results - Investing.com India
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors - The Manila Times
Monte Rosa's Cancer Drug MRT-2359 Shows Promising Safety Profile in Phase 1/2 Trial - StockTitan
Monte Rosa Therapeutics: A First Assessment (NASDAQ:GLUE) - Seeking Alpha
Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High? - MSN
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference - The Manila Times
Monte Rosa Therapeutics CEO to Present at Piper Sandler Healthcare Conference | GLUE Stock News - StockTitan
Monte Rosa Therapeutics Inc (GLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.69%
4.93%
자본화:
|
볼륨(24시간):